Trials / Conditions / Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified

Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified

7 registered clinical trials studyying Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell T NCT07365306	City of Hope Medical Center	Phase 2
Recruiting	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812	National Cancer Institute (NCI)	Phase 2
Recruiting	Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for NCT06905509	Joseph Tuscano	Phase 2
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373	Mayo Clinic	Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2